Journal
DRUG DESIGN DEVELOPMENT AND THERAPY
Volume 13, Issue -, Pages 3657-3667Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/DDDT.S217826
Keywords
olmesartan medoxomil; angiotensin II; renal injury; diabetic nephropathy; db/db mice
Categories
Funding
- National Natural Science Foundation of China [81600529]
- Fundamental Research Funds for the Central Universities [17ykpy64]
- Science and Technology Program of Zhuhai, China [20181117E030069]
Ask authors/readers for more resources
Background: Diabetic nephropathy (DN) is a common complication of diabetes mellitus (DM) and also a major cause of end-stage renal disease (ESRD). Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and has been shown to exhibit renoprotective effects on a streptozotocin (STZ)-induced diabetic rat model. Yet, whether OM affects DN progression and renal injury in db/db mice, a type 2 diabetic murine model, has not been established. Methods: Wild-type (n = 15) and db/db mice (n = 15) were treated with control saline or OM via oral gavage. The physiological and biochemical parameters were evaluated and histological examinations of kidney specimens were performed. Results: Compared with saline-treated db/db mice, db/db mice administered with OM showed ameliorated diabetic physiological and biochemical parameters. In addition, OM decreased urinary albumin excretion and plasma creatinine level in db/db mice. Moreover, histologically, OM reduced glomerular hypertrophy and injury, and also ameliorated tubular injury, thus suggesting that OM improves renal function and minimizes renal pathological deterioration in db/db mice. Conclusion: Our study reveals a beneficial role of OM in ameliorating DN in db/db mice, which is associated with its renoprotective function.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available